Loading
A phase 3 trial of Izalontamab brengitecan in ovarian cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) is a phase 3 interventional study registered as NCT06994195 by Sichuan Baili Pharmaceutical Co., Ltd., with 450 participants planned, started 2025-08-04 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan. Conditions listed: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/